| Human immunodeficiency virus I infection
Edurant vs Genvoya
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Edurant vs Genvoya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGenvoya has a higher rate of injection site reactions vs Edurant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Genvoya but not Edurant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edurant
Genvoya
At A Glance
Oral
Once daily
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Oral
Once daily
Fixed-dose combination: INSTI + CYP3A inhibitor + NRTIs
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 25 mg oral tablet once daily with a meal for patients weighing at least 25 kg. Pediatric patients 2 years and older weighing 14-20 kg receive 12.5 mg (5 x 2.5 mg dispersed tablets); 20-25 kg receive 15 mg (6 x 2.5 mg dispersed tablets). During pregnancy with virologic suppression, 25 mg once daily with a meal. When coadministered with rifabutin, increase to 50 mg (two 25 mg tablets) once daily with a meal.
Human immunodeficiency virus I infection One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) orally once daily with food in patients weighing at least 25 kg with creatinine clearance >=30 mL/min, or adults with creatinine clearance <15 mL/min receiving chronic hemodialysis (administer after hemodialysis on dialysis days).
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (more than single-dose treatment)
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Alfuzosin
- Carbamazepine
- Phenobarbital
- Phenytoin
- Rifampin
- Lurasidone
- Pimozide
- Dihydroergotamine
- Ergotamine
- Methylergonovine
- St. John's wort
- Lomitapide
- Lovastatin
- Simvastatin
- Sildenafil for pulmonary arterial hypertension
- Triazolam
- Orally administered midazolam
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, rash, dizziness, nausea, abdominal pain, vomiting, fatigue
Serious Skin and hypersensitivity reactions including DRESS, hepatotoxicity, depressive disorders
Postmarketing Nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common (>=5%) Nausea, diarrhea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
GENVOYA is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor that prevents HIV-1 DNA integration into host genomic DNA), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine (a nucleoside reverse transcriptase inhibitor that causes viral DNA chain termination), and tenofovir alafenamide (a prodrug converted to tenofovir diphosphate, which inhibits reverse transcriptase through DNA chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edurant
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (11/12)
Genvoya
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Edurant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Genvoya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Edurant
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Genvoya
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdurantView full Edurant profile
GenvoyaView full Genvoya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.